A detailed history of Tower Research Capital LLC (Trc) transactions in Day One Biopharmaceuticals, Inc. stock. As of the latest transaction made, Tower Research Capital LLC (Trc) holds 1,054 shares of DAWN stock, worth $13,480. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,054
Previous 23,649 95.54%
Holding current value
$13,480
Previous $325,000 95.69%
% of portfolio
0.0%
Previous 0.01%

Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$12.72 - $16.03 $287,408 - $362,197
-22,595 Reduced 95.54%
1,054 $14,000
Q2 2024

Aug 13, 2024

BUY
$12.03 - $17.69 $264,046 - $388,277
21,949 Added 1291.12%
23,649 $325,000
Q1 2024

May 15, 2024

SELL
$13.56 - $17.46 $2,779 - $3,579
-205 Reduced 10.76%
1,700 $28,000
Q4 2023

Feb 13, 2024

BUY
$9.68 - $15.37 $2,052 - $3,258
212 Added 12.52%
1,905 $27,000
Q3 2023

Nov 14, 2023

SELL
$11.22 - $14.86 $16,583 - $21,963
-1,478 Reduced 46.61%
1,693 $20,000
Q2 2023

Aug 14, 2023

SELL
$11.74 - $14.47 $42,440 - $52,309
-3,615 Reduced 53.27%
3,171 $37,000
Q1 2023

May 09, 2023

BUY
$12.75 - $23.41 $55,462 - $101,833
4,350 Added 178.57%
6,786 $91,000
Q4 2022

Feb 10, 2023

BUY
$18.77 - $22.0 $4,692 - $5,500
250 Added 11.44%
2,436 $53,000
Q3 2022

Nov 10, 2022

SELL
$16.44 - $26.57 $25,712 - $41,555
-1,564 Reduced 41.71%
2,186 $44,000
Q2 2022

Aug 15, 2022

BUY
$5.72 - $17.9 $11,096 - $34,726
1,940 Added 107.18%
3,750 $67,000
Q1 2022

May 12, 2022

BUY
$9.12 - $17.47 $6,958 - $13,329
763 Added 72.87%
1,810 $18,000
Q4 2021

Feb 14, 2022

BUY
$15.65 - $26.33 $8,028 - $13,507
513 Added 96.07%
1,047 $17,000
Q3 2021

Nov 15, 2021

BUY
$20.0 - $27.92 $10,480 - $14,630
524 Added 5240.0%
534 $12,000
Q2 2021

Aug 16, 2021

BUY
$19.0 - $23.69 $190 - $236
10 New
10 $0

Others Institutions Holding DAWN

About Day One Biopharmaceuticals, Inc.


  • Ticker DAWN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 73,461,104
  • Market Cap $940M
  • Description
  • Day One Biopharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops and commercializes targeted therapies for patients with genetically defined cancers. Its lead product candidate is DAY101, an oral brain-penetrant type II pan-rapidly accelerated fibrosarcoma kinase inhibitor that is in Phase II clinical trial for pediatric pa...
More about DAWN
Track This Portfolio

Track Tower Research Capital LLC (Trc) Portfolio

Follow Tower Research Capital LLC (Trc) and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Tower Research Capital LLC (Trc), based on Form 13F filings with the SEC.

News

Stay updated on Tower Research Capital LLC (Trc) with notifications on news.